Advisory - Several store-brand pain or sinus relief tablets recalled because consumers may be unable to access important safety information
OTTAWA, Nov. 7, 2018 /CNW/ -
Issue Vita Health Products is voluntarily recalling several store-brand (Care+, Exact, Life, and Pharmasave) over-the-counter drugs used for pain or sinus relief because of a labelling issue. Consumers may be unable to peel open the wrap-around label on the bottle to access the warning statements, or the label may not peel off completely, which may make it difficult to read some of the important safety information.
This issue is the result of a label manufacturing defect affecting some bottles and does not affect the safety or effectiveness of the product in the bottles. The labelling defect means that some consumers may not be able to access important safety information, such as warnings and instructions for product storage.
Vita Health Products has advised Health Canada that only the products listed below are affected by this issue. The products were distributed at major drug and grocery retail chains across Canada.
Who is affected
Consumers who have bought the affected products listed in the table below.
Affected products
Description
DIN
Lot
Expiry
Units Distributed
Care+ brand
Extra Strength Muscle & Back
Pain Relief
40 count package
02239141
7L3044GZZ
JL/2020
2,973
02239141
8E2054L0W
NO/2020
1,563
02239141
8I1954ML4
MR/2021
1,489
Exact brand
Extra Strength Head Cold and Sinus
24 count package
02248646
8B2924GZW
JA/2021
576
Life brand
Muscle & Back Pain Relief-8
50 count package
02242180
7J1944M54
SE/2020
3,864
Life brand
Extra Strength Muscle & Back Pain Relief
40 count package
02239141
8E2054HLA
NO/2020
7,146
Pharmasave brand
Extra Strength Acetaminophen Tablets 500 mg
200 count package
00605778
8E3264KQS
AL/2021
1,022
What consumers should do
Check if your product has a label that does not peel back. If it does not peel back, return the product to the place of purchase, or call the Vita Health Customer Contact Centre at 1?877?637?7557, Monday to Friday 9:00 am to 5:30 pm ET for further instruction.
Consult your health care professional if you have used these products and have health concerns.
Health Canada is monitoring the company's recall. Should additional safety concerns be identified related to this issue, Health Canada will take appropriate action and inform Canadians as necessary.
Stay connected with Health Canada and receive the latest advisories and product recalls.
Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSAtm (vibegron under the international...
Sustain Exchange LLC is proud to announce a partnership with HearMe, a leading behavioral health peer support platform focused on ensuring healthy lives and promoting well-being. As part of this innovative partnership, SustainAble Exchange will...
C?N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today announced a partnership agreement with Mediford Corporation, a PHC Holdings Corporation (TSE 6523) Group Company and premier...
BeiGene, Ltd. , a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company's strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets.
This...
Invensify, Inc., Santa Clara, California, has introduced a power efficient, temperature-controlled shipping container designed to maintain stable storage temperatures for high-value pharmaceuticals before and during transport to last-mile cold chain...
Oligonucleotide Synthesis Market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at a CAGR of 17.5% from 2024 to 2029 according to a new report by MarketsandMarketstm.
One of...